ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-CD19/CD20 CAR-T Cells KITE-363

Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Lymphoma, B-Cell · Lupus Nephritis, led by Gilead Sciences.

Drug pageAutologous Anti-CD19/CD20 CAR-T Cells KITE-363: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 26, 20213 company-led studies, 3 open or runningNext primary completion: Feb 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences33 open or runningphase 2since Jul 26, 2021Jul 26, 2021Feb 2030phase 2 · NCT04989803

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2021First study: phase 2 study in Relapsed and/or Refractory B-cell LymphomaFirst studyNCT04989803 · 247 enrolled · United States, Australia, Canada and more
  2. Jun 18, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07038447 · 52 planned · United States, Australia, Canada and more
  3. Dec 12, 2025Phase 1 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07304154 · 57 planned · United States, Australia, Canada
  4. Sep 28, 2026Primary completion moved from 2029-07 to 2030-09Date moved laterphase 1 · +14 months · NCT07038447
  5. Nov 17, 2026Primary completion moved from 2029-06 to 2031-12Date moved laterphase 1 · +30 months · NCT07304154

Ahead

  1. Feb 2030Primary completion: phase 2 study in Relapsed and/or Refractory B-cell LymphomaNCT04989803
  2. Sep 2030Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07038447
  3. Dec 2031Primary completion: phase 1 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07304154

TargetBeta

CD19 →MS4A1 →read by rule
“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
prizloncabtagene autoleucelruleAbelZetaphase 22
GSK5926371GlaxoSmithKlinephase 22
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleavencell-therapeutics-incphase 21
CT204V-CD19 × CD20ruleAstraZenecaphase 21
HB2198rulehinge-biophase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07304154Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada1RecruitingDec 203157
NCT07038447Lupus Erythematosus, Systemic · United States, Australia, Canada and more1By invitationSep 203052
NCT04989803Relapsed and/or Refractory B-cell Lymphoma · United States, Australia, Canada and more2Active, not recruitingFeb 2030247

How it is read

Names in the registry

  • “KITE-363”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.